The latest price target for RxSight (NASDAQ:RXST) was reported by Jefferies on October 29, 2024. The analyst firm set a price target for $72.00 expecting RXST to rise to within 12 months (a possible 59.82% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for RxSight (NASDAQ:RXST) was provided by Jefferies, and RxSight initiated their buy rating.

The last upgrade for RxSight Inc happened on December 13, 2023 when Wells Fargo raised their price target to $42. Wells Fargo previously had an equal-weight for RxSight Inc.

The last downgrade for RxSight Inc happened on December 12, 2022 when Wells Fargo changed their price target from $20 to $14 for RxSight Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RxSight, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RxSight was filed on October 29, 2024 so you should expect the next rating to be made available sometime around October 29, 2025.

While ratings are subjective and will change, the latest RxSight (RXST) rating was a initiated with a price target of $0.00 to $72.00. The current price RxSight (RXST) is trading at is $45.05, which is within the analyst’s predicted range.